Last reviewed · How we verify
Anti-VEGF drug
The anti-VEGF drug developed by Xiaodong Sun is an investigational therapy that has not yet received FDA approval. The drug aims to inhibit vascular endothelial growth factor (VEGF) to treat various ophthalmic conditions, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Despite its promising mechanism, the drug is still in the clinical trial phase, and no safety or efficacy data have been publicly disclosed. The company is focusing on advancing the drug through regulatory pathways to potentially bring it to market. Given the competitive landscape of anti-VEGF therapies, the drug will need to demonstrate significant advantages to gain market traction.
At a glance
| Generic name | Anti-VEGF drug |
|---|---|
| Also known as | Aflibercept (Eylea) |
| Sponsor | Xiaodong Sun |
| Drug class | Anti-VEGF |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-VEGF drug CI brief — competitive landscape report
- Anti-VEGF drug updates RSS · CI watch RSS
- Xiaodong Sun portfolio CI